Outcomes when Switching from a pro re nata Regimen to a Treat and Extend Regimen Using Aflibercept in Neovascular Age-Related Macular Degeneration

Publisher： Karger

E-ISSN： 1423-0267|236|4|201-206

ISSN： 0030-3755

Source： Ophthalmologica, Vol.236, Iss.4, 2016-12, pp. : 201-206

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Baseline Optical Coherence Tomography Findings as Outcome Predictors after Switching from Ranibizumab to Aflibercept in Neovascular Age-Related Macular Degeneration following a Treat-and-Extend Regimen

By  

Ophthalmologica, Vol. 238, Iss. 3, 2017-08 ,pp. : 172-178

Karger

Access to resources Recommend Favorite

One-Year Outcomes of 1 + pro re nata versus 3 + pro re nata Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 237, Iss. 2, 2017-02 ,pp. : 105-110

Karger

Access to resources Recommend Favorite

One-Year Outcomes of a Treat-and-Extend Regimen of Aflibercept for Exudative Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 237, Iss. 3, 2017-03 ,pp. : 139-144

Karger

Access to resources Recommend Favorite

Comparison of pro re nata versus Bimonthly Injection of Intravitreal Aflibercept for Typical Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 238, Iss. 1-2, 2017-04 ,pp. : 17-22

Karger

Access to resources Recommend Favorite

Fluctuations in Pigment Epithelial Detachment and Retinal Fluid Using a Bimonthly Treatment Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 235, Iss. 1, 2016-0 ,pp. : 42-48

Karger

Access to resources Recommend Favorite